ArticleCurrent drug discovery technologies2025
Article in Current drug discovery technologies, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionAngina pectoris, a common cardiovascular condition, necessitates the development of effective therapeutic agents. Nisoldipine, a calcium channel blocker, and its analogues have shown potential in treating this condition. However, the optimization of these compounds for enhanced therapeutic efficacy remains a critical challenge.
objectiveThis study aimed to investigate the therapeutic potential of Nisoldipine analogues through in silico analysis, with the goal of identifying lead compounds for the treatment of angina pectoris and optimizing their formulation for improved solubility and drug release.
methodsEighteen Nisoldipine derivatives were screened using RESULTS AND DISCUSSION: ZINC26826387 emerged as the most promising Nisoldipine analogue, exhibiting superior solubility, absence of AMES toxicity, strong molecular docking interaction with the target protein (docking score of -8.0 kcal/mol), and favourable pharmacokinetic properties. MD simulation confirmed the stability of the ligand-receptor complex. The study also identified 88 target hub genes associated with angina pectoris, with PTGS2 prioritized as a key gene. The nanoparticle formulation of ZINC26826387 significantly enhanced solubility by 2.53-fold compared to the unformulated compound. The optimized nanoparticle tablets achieved a 98.53% drug release within 30 minutes, with an average particle size of 50 nm, entrapment efficiency of 98.89%, and zeta potential of -52 mV, indicating good stability and uniformity.
conclusionThe study demonstrates the therapeutic potential of ZINC26826387, a Nisoldipine analogue, through its enhanced solubility and reduced crystallinity. The lead compound was made into Nanoparticles using Pluronic F407 as carrier. These nanoparticles were further formulated to oral disintegrating tablets for rapid drug release, good stability compared to conventional tablets. These findings suggest that ZINC26826387 could be a promising candidate for the treatment of angina pectoris.
Indexed as
Identifiers
40257029What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.